Valeant price target raised to $75 from $64 at Jefferies Jefferies says Valeant's 2012 guidance was even better than its optimistic forecasts, and finds the company's goal of being a top 15 Pharma company by the end of 2013 intriguing. The firm says the goal would equate to a $160 per share valuation. Jefferies raised its price target for Valeant shares and keeps a Buy rating on the stock.
News For VRX From The Last 14 Days
Check below for free stories on VRX the last two weeks.